Investors Overview Overview Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Corporate Factsheet Annual Reports Overview FRONT >> Quick Links Stock Info News Releases SEC Filings Analyst Coverage Presentations & Events Corporate Factsheet News Releases Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 FRONT >> News > View All View All News Events Nov 09 2022 at 4:30 PM EST Third Quarter 2022 Financial Results Oct 31 2022 at 10:00 AM EDT Cyclacel Hosting Research & Development Day Aug 10 2022 at 4:30 PM EDT Second Quarter 2022 Financial Results FRONT > Events - View All View All Events Featured Videos CEO Spiro Rombotis addressing Cancer Resistance Toolkit Email AlertsRSS FeedsPrint Page
Overview FRONT >> Quick Links Stock Info News Releases SEC Filings Analyst Coverage Presentations & Events Corporate Factsheet News Releases Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 FRONT >> News > View All View All News Events Nov 09 2022 at 4:30 PM EST Third Quarter 2022 Financial Results Oct 31 2022 at 10:00 AM EDT Cyclacel Hosting Research & Development Day Aug 10 2022 at 4:30 PM EDT Second Quarter 2022 Financial Results FRONT > Events - View All View All Events Featured Videos CEO Spiro Rombotis addressing Cancer Resistance
Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
